Patient Financing And HCP Marketing Will Transform This Healthcare Platform Over The Next Decade

Catalysts

About Phreesia

Phreesia provides a software driven platform that digitises patient intake, payments and engagement for healthcare providers and life sciences companies.

What are the underlying business or industry changes driving this perspective?

• Rising patient financial responsibility is pushing providers to look for tools that convert receivables into more predictable cash flow. Phreesia’s expansion into provider financing through AccessOne directly targets this need, with take rates in the 4% to 12% range that could support revenue and EBITDA growth.
• Hospitals and health systems are experiencing fewer days cash on hand and longer collection cycles. AccessOne’s funded and unfunded models, including the relationship with PNC Bank, are designed to shorten days outstanding, which can support higher payment related revenue and help protect margins.
• Phreesia is extending its patient marketing engine into a multibillion dollar healthcare provider digital marketing opportunity. Early HCP activation pilots using MediFind and PhreesiaOnCall aim to create an additional, differentiated revenue stream within Network Solutions that can support revenue per client and earnings.
• A long standing presence with thousands of provider organisations and top 10 pharma companies, combined with deeply embedded workflows and permission based engagement, positions Phreesia to coordinate messages to both patients and clinicians. This can support premium pricing, higher Network Solutions revenue and improved net margins.
• Consistent growth in total revenue per Average Healthcare Services Client to US$26,622 and a focus on attaching more products such as AI driven intake, voice AI and post visit engagement create more ways to monetise each client relationship. This can support revenue expansion, operating leverage and earnings.

Assumptions

This narrative explores a more optimistic perspective on Phreesia compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts. How have these above catalysts been quantified?

• The bullish analysts are assuming Phreesia's revenue will grow by 13.7% annually over the next 3 years.
• The bullish analysts assume that profit margins will increase from -1.2% today to 17.0% in 3 years time.
• The bullish analysts expect earnings to reach $116.2 million (and earnings per share of $1.82) by about January 2029, up from $-5.4 million today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as $42.0 million.
• In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 24.9x on those 2029 earnings, up from -193.2x today. This future PE is lower than the current PE for the US Healthcare Services industry at 52.0x.
• The bullish analysts expect the number of shares outstanding to grow by 2.58% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 8.26%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• AccessOne currently is not suitable for most of Phreesia's client base and management plans to invest in product and go to market over multiple quarters before wider cross sell is possible, so if those investments do not gain traction, the expected new growth lever from provider financing may fall short and weigh on revenue and earnings.
• AccessOne operates with operating costs at 65% to 75% of revenue and the acquisition was funded with approximately US$53 million of cash and a US$110 million secured bridge loan that management plans to refinance, so if credit markets tighten or funding costs rise, the combination of a relatively high cost structure and higher interest expense could pressure net margins and free cash flow.
• Most of the financial risk in AccessOne's funded and unfunded models remains with healthcare providers, and providers are already facing longer payment cycles and fewer days cash on hand, so any sustained stress on hospital and health system finances could reduce demand for new financing programs and limit growth in payment related revenue and earnings.
• Network Solutions is exposed to life sciences DTC advertising budgets and management explicitly called out fluidity in the selling season and DTC related regulatory questions, so if pharma companies pull back or reallocate spend over time, that could slow Network Solutions growth and cap improvements in revenue per client and operating leverage.
• The new HCP marketing and PhreesiaOnCall offerings are still in early pilot stages with ad formats and workflows being tested, and if providers or pharma clients do not adopt these programs at scale or treat them as incremental rather than core spend, the expected multibillion dollar HCP marketing opportunity may not translate into the double digit revenue per AHSC growth that underpins higher earnings.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bullish price target for Phreesia is $35.0, which represents up to two standard deviations above the consensus price target of $29.82. This valuation is based on what can be assumed as the expectations of Phreesia's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $35.0, and the most bearish reporting a price target of just $24.0.
  
• In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2029, revenues will be $681.7 million, earnings will come to $116.2 million, and it would be trading on a PE ratio of 24.9x, assuming you use a discount rate of 8.3%.
  
• Given the current share price of $17.24, the analyst price target of $35.0 is 50.7% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.